Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report

Kirby Taylor; Layla Ghergherehchi; Prethy Rao; C Armitage Harper 3rd; Emmanuel Chang

doi:10.1016/j.jaapos.2021.02.004

Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report

J AAPOS. 2021 Jun;25(3):180-184. doi: 10.1016/j.jaapos.2021.02.004. Epub 2021 May 6.

Authors

Kirby Taylor¹, Layla Ghergherehchi², Prethy Rao³, C Armitage Harper 3rd⁴, Emmanuel Chang⁵

Affiliations

¹ Texas A&M College of Medicine, College Station, Texas.
² Ruiz Department of Ophthalmology and Visual Science, McGovern Medical School at The University of Texas Health Science Center, Houston, Texas, and Robert Cizik Eye Clinic, Houston, Texas.
³ Retina and Vitreous of Texas, Houston, Texas.
⁴ Austin Retina Associates, University of Texas Dell School of Medicine, Austin, Texas, and University of Texas San Antonio, San Antonio, Texas.
⁵ Retina and Vitreous of Texas, Houston, Texas. Electronic address: emanmdphd@gmail.com.

PMID: 33964455
DOI: 10.1016/j.jaapos.2021.02.004

Abstract

We report the case of 10-year-old girl who developed retinal neovascularization and vitreous hemorrhage 10 years after successful treatment of type 1 retinopathy of prematurity infant with intravitreal bevacizumab without laser ablation therapy.

Publication types

Case Reports

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
Child
Female
Gestational Age
Humans
Infant
Infant, Newborn
Intravitreal Injections
Laser Coagulation
Retinopathy of Prematurity* / surgery
Vascular Endothelial Growth Factor A

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Bevacizumab